focus -WSS

focus

author：hotspot 2025-10-01 13:58:26 - browse：644

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Weight loss drug costs may need more research, senator suggests

hotspot

WSS

Congress must reauthorize a committee to support older Americans

Childhood cancer progress stalls for Black, Hispanic kids: Report

Intellia reports positive results for its CRISPR

Hospitals look to new technology to keep health care workers safe

World's first CRISPR

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

hotspot

focus

focus

The cancer drug shortage isn’t new — and neither are the solutions

David Sabatini, ex

Medical records are filled with copy

Letters to First Opinion on caregivers, digital health, and more

Hepatitis C has a cure — but many Americans still lack access to it

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Medicare details structure of new drug price negotiation program

Morphosys mixed study results for blood cancer drug

State Dept. review finds Biden bears some blame for Afghanistan failures

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

focus

HIV drugs protect against transmission, even in unprotected sex

Intellia reports positive results for its CRISPR

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Childhood cancer progress stalls for Black, Hispanic kids: Report

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Shifting the focus from loneliness to social health

explore

focus

hotspot

knowledge